Please login to the form below

Not currently logged in
Email:
Password:

Boehringer to research cause of diabetes with German university

Five-year collaboration with TU Dresden will also look at link between high blood sugar levels and diabetes complications

Boehringer Ingelheim has signed a pact with the Technische Universität (TU) in Dresden to research the cause of type 1 diabetes.

The German pharma firm said results from a range of planned studies may help to design new medicines and improve understanding of how diabetes drugs can be made into more personalised medicines.

Boehringer will work with the university's department of medicine and GWT, a private R&D company based within TU Dresden, in a five-year collaboration that will also look at the link between high blood sugar and complications associated with diabetes.

The research partners will focus on six projects that cover preclinical findings and investigational treatments and how they translate to clinical situations with patients.

These projects include research into the destruction of insulin-producing beta cells - the genetic cause of type 1 diabetes - for which a reason is still unknown.

Further research will look at the molecular reasons behind diabetic complications in parts of the body like eyes, kidneys, nerves and skin.

The collaboration has a similar purpose as Novo Nordisk's planned type 1 diabetes research centre in Seattle, US.

This will also take a translational approach, combining basic research and early proof-of-concept trials to ensure investigations can develop quickly from animal models into exploratory trials.

The moves follow a trend to more research into type 1 diabetes, incidents of which are growing alongside type 2 diabetes, but for less certain reasons.

It is estimated that 366m people currently live with either form of the condition worldwide, according to the International Diabetes Federation (IDF), with 78,000 children developing type 1 diabetes every year.

Other firms to increase research efforts into the condition include Sanofi, which is also collaborating with an academic institution after signing a $3.1m alliance with the University of California.

6th February 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

The patient will see you now
GCI Health’s Laura Starr and Chris Bath report on how the dawning era of mobile tech and the ‘Internet of Things’ has transformed the health and wellness arena....
When forecasters take the floor: 6 tips on presenting a forecast
Peter Mansell queries some of pharma’s leading forecasters for their dos and don’ts on presenting a forecast...
Enablers of drug innovation could lie in the numbers
Christopher Ehinger of Black Swan Analysis addresses the problem of clinical-trial recruitment as a barrier to new drug development and offers a new way of looking at the problem....

Infographics